To study the effect of inhibition of hyperpolarization-activated cyclic nucleotide-gated cation channel (HCN) on spatial memory with cerebral ischemia-reperfusion (IR) in rats, the middle cerebral artery occlusion was performed to induce the IR injury. ZD7288 (5 µg/µl) and MK-801 (100 µg/µl) were administrated by lateral ventricular injection. Except for the sham group, all other groups were subjected to ischemia for 2 h followed by reperfusion for 4 weeks. The neurological impairment was evaluated using the neurological deficit score, and the Morris water maze detected changes in spatial memory. The cerebral infarction volume was determined by TTC staining, and the morphology and number of hippocampal neurons on the ischemic side were observed through HE staining. Immunoblotting and qPCR were used to detect the expressions of HCN1, HCN2, and N-methyl-D-aspartic acid receptor (NMDAR) subunits in the hippocampus. The expression changes of NMDAR subunits were applied by immunohistochemistry in different hippocampus regions. Our study found that ZD7288 could improve the spatial memory deficits induced by IR and exert neuroprotective effects. The possible mechanism is related to the fact that ZD7288 regulates the expression of various subunits of NMDAR by inhibiting HCN, including its effect on their phosphorylation states.
Zinc finger proteins (ZFPs), a vast superfamily of sequence-specific DNA and RNA-binding proteins, serve as master regulators of gene expression and cellular homeostasis. While traditionally studied for their roles in development, ZFPs have emerged as critical effectors and therapeutic targets across a wide spectrum of human pathologies, including cancer, neurological disorders, and autoimmune diseases. This review systematically dissects the molecular mechanisms by which dysregulated ZFP activity drives disease pathogenesis, using ischemic stroke as a central exemplar to illustrate their multifaceted roles. We detail how specific ZFPs orchestrate key stroke risk factors such as hypertension, hyperglycemia, and atherosclerosis, subsequently govern post-ischemic injury cascades, including neuroinflammation, programmed cell death, and blood–brain barrier disruption. Addressing the long-standing challenge of ZFPs as “undruggable” targets, we critically evaluate cutting-edge therapeutic strategies poised to modulate their function with precision. These include small-molecule modulators, targeted protein degraders (PROTACs), zinc finger nuclease (ZFN)-based gene editing, and advanced nanocarrier delivery systems, complemented by high-throughput computational screening. By integrating deep mechanistic insights with novel translational approaches, this review establishes a pioneering pan-disease framework for targeting ZFP networks. We provide a structured roadmap for future research and highlight the immense potential of ZFPs as a new class of master regulatory targets for developing novel and feasible therapies in ischemic stroke and beyond.
Apoptosis is the crucial pathological mechanism following cerebral ischemic injury. Our previous studies demonstrated that clonidine, one agonist of alpha2-adrenergic receptor (α2-AR), could attenuate cerebral ischemic injury in a rat model of Middle cerebral artery occlusion/reperfusion (MCAO/R). However, it’s unclear whether clonidine exerts neuroprotective effects by regulating neuronal apoptosis. In this study, we elucidated whether clonidine can exert anti-apoptotic effects in cerebral ischemic injury, and further explore the possible mechanisms. Neurological deficit score was measured to evaluate the neurological function. TTC staining was used for the measurement of brain infarct size. Hematoxylin-Eosin (HE) staining was applied to examine the cell morphology. TUNEL and DAPI fluorescent staining methods were used to analyze the cell apoptosis in brain tissue. Western blotting assay was applied to detect the protein expression of Caspase-3 and P53. Fluorescence quantitative real-time PCR was performed to assess the gene expression of Caspase-3 and P53. The results showed that clonidine improved neurological function, reduced brain infarct size, alleviated neuronal damage, and reduced the ratio of cell apoptosis in the brain with MCAO/R injury. moreover, clonidine down-regulated the protein and gene expression of Caspase-3 and P53 which were over-expressed after MCAO/R injury. Whereas, yohimbine (one selective α2-AR antagonist) mitigated the anti-apoptosis effects of clonidine, accompanied by reversed gene and protein expression changes. The results indicated that clonidine attenuated cerebral MCAO/R injury via suppressing neuronal apoptosis, which may be mediated, at least in part, by activating α2-AR.